Maria-Luisa Maccecchini
Chief Executive Officer at ANNOVIS BIO, INC.
Net worth: 15 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Hoffman | M | 73 |
Translational Development Acquisition Corp.
 Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | 10 years |
| Donald F. Weaver | M | - |
Treventis Corp.
 Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| Donald Keyser | M | 71 | 6 years | |
| Panna Sharma | M | 53 | 6 years | |
| Claudine Bruck | M | 68 | 9 years | |
| Timothy J. Williamson | M | - |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| Greg Harriman | M | - |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| Christopher J. Barden | M | - |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| Vijay Chandru | M | 70 | 5 years | |
| Reid McCarthy | M | 70 | 3 years | |
| L. William McIntosh | M | 77 |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| David Margrave | M | 64 | 6 years | |
| Paul Brooke | M | 77 |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | - |
| Mark White | M | 68 | 8 years | |
| Kishor Bhatia | M | 69 | 5 years | |
| Gregory Kopia | M | - |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| Avanindra Das | M | 38 |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | 2 years |
| Reggie Ewesuedo | M | - | 1 years | |
| Cheng Fang | M | - | 3 years | |
| Melissa Gaines | F | - | - | |
| Mark A. Reed | M | - |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | - |
| David Silberstein | M | 73 | 6 years | |
| Susan Kennedy | F | 62 |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | - |
| Ernest Kitt | M | - | 1 years | |
| Eve M. Damiano | F | - | 2 years | |
| E. Premkumar Reddy | M | 80 |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | - |
| Curtis T. Keith | M | 53 |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | - |
| Bruce C. Galton | M | 72 |
Annovis, Inc.
 Annovis, Inc. Chemicals: SpecialtyProcess Industries Annovis, Inc. develops, manufactures, and markets a wide variety of nucleic acid based for the life sciences sector. The company is headquartered in Aston, PA. | 24 years |
| Andrew Walsh | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leslie W. Kreis | M | 52 | 3 years | |
| Henry Hagopian | M | 56 | 2 years | |
| Robert Whelan | M | 72 | 5 years | |
| Desh S. K. Govender | M | - | - | |
| Jeffrey McGroarty | M | 54 | 3 years | |
| Nicole Leber | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 28 | 80.00% |
| Canada | 7 | 20.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Maria-Luisa Maccecchini
- Personal Network
